Limits...
Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naïve Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study.

Liu CH, Sheng WH, Sun HY, Hsieh SM, Lo YC, Liu CJ, Su TH, Yang HC, Liu WC, Chen PJ, Chen DS, Hung CC, Kao JH - Sci Rep (2015)

Bottom Line: Data are limited on the effectiveness and safety of peginterferon plus ribavirin in HIV-infected Asian patients with acute or chronic HCV infection.The primary endpoint was sustained virologic response (SVR), defined as undetectable HCV RNA 24 weeks off-therapy.In conclusion, the SVR rates of peginterferon plus ribavirin for 24 weeks and for response-guided 12-72 weeks are satisfactory in HIV-infected Taiwanese patients with acute and chronic HCV infection.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.

ABSTRACT
Data are limited on the effectiveness and safety of peginterferon plus ribavirin in HIV-infected Asian patients with acute or chronic HCV infection. HIV-infected Taiwanese patients with acute HCV infection received peginterferon plus weight-based ribavirin for 24 weeks (n = 24), and those with chronic HCV genotype 1 or 6 (HCV-1/6) and HCV genotype 2 or 3 (HCV-2/3) infection received response-guided therapy for 12-72 and 24-48 weeks, respectively (n = 92). The primary endpoint was sustained virologic response (SVR), defined as undetectable HCV RNA 24 weeks off-therapy. The SVR rates were 83% and 72% in patients with acute and chronic HCV infection (p = 0.30), and 68% and 72% in patients with chronic HCV-1/6 and HCV-2/3 infection (p = 0.48), respectively. While no factors predicted SVR in acute HCV and chronic HCV-2/3 infection, age (odds ratio [OR] per 1-year increase: 0.88, 95% confidence interval [CI]: 0.78-0.99, p = 0.04), HCV RNA (OR per 1-log10 increase: 0.18, 95% CI: 0.03-0.98, p = 0.03), IL28B genotype (OR: 5.52, 95% CI: 1.55-12.2, p = 0.02), and RVR (OR: 9.62, 95% CI: 3.89-15.3, p = 0.007) predicted SVR in chronic HCV-1/6 infection. In conclusion, the SVR rates of peginterferon plus ribavirin for 24 weeks and for response-guided 12-72 weeks are satisfactory in HIV-infected Taiwanese patients with acute and chronic HCV infection.

No MeSH data available.


Related in: MedlinePlus

Flow diagram of HIV-infected patients with acute or chronic HCV infection according to treatment status.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4663763&req=5

f1: Flow diagram of HIV-infected patients with acute or chronic HCV infection according to treatment status.

Mentions: Among the 34 patients with documented acute HCV infection, 5 did not receive treatment because of spontaneous viral clearance in 4 (11.8%) and decline for treatment in 1 (2.9%). Five of the 29 treated patients were excluded from the analysis because of ongoing treatment in 3 and post-treatment follow-up <24 weeks in 2. Among the 116 patients with chronic HCV infection, 7 did not receive treatment because of decline for treatment in 4, lymphopenia in 2, and decompensated cirrhosis in 1. Seventeen of the 109 treated patients were excluded from the analysis because of ongoing treatmentin 11, post-treatment follow-up <24 weeks in 4, and hepatitis B virus (HBV) coinfection in 2. Finally, 24 and 92 HIV-infected patients with acute and chronic HCV infections were included in the study, respectively (Fig. 1).


Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naïve Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study.

Liu CH, Sheng WH, Sun HY, Hsieh SM, Lo YC, Liu CJ, Su TH, Yang HC, Liu WC, Chen PJ, Chen DS, Hung CC, Kao JH - Sci Rep (2015)

Flow diagram of HIV-infected patients with acute or chronic HCV infection according to treatment status.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4663763&req=5

f1: Flow diagram of HIV-infected patients with acute or chronic HCV infection according to treatment status.
Mentions: Among the 34 patients with documented acute HCV infection, 5 did not receive treatment because of spontaneous viral clearance in 4 (11.8%) and decline for treatment in 1 (2.9%). Five of the 29 treated patients were excluded from the analysis because of ongoing treatment in 3 and post-treatment follow-up <24 weeks in 2. Among the 116 patients with chronic HCV infection, 7 did not receive treatment because of decline for treatment in 4, lymphopenia in 2, and decompensated cirrhosis in 1. Seventeen of the 109 treated patients were excluded from the analysis because of ongoing treatmentin 11, post-treatment follow-up <24 weeks in 4, and hepatitis B virus (HBV) coinfection in 2. Finally, 24 and 92 HIV-infected patients with acute and chronic HCV infections were included in the study, respectively (Fig. 1).

Bottom Line: Data are limited on the effectiveness and safety of peginterferon plus ribavirin in HIV-infected Asian patients with acute or chronic HCV infection.The primary endpoint was sustained virologic response (SVR), defined as undetectable HCV RNA 24 weeks off-therapy.In conclusion, the SVR rates of peginterferon plus ribavirin for 24 weeks and for response-guided 12-72 weeks are satisfactory in HIV-infected Taiwanese patients with acute and chronic HCV infection.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.

ABSTRACT
Data are limited on the effectiveness and safety of peginterferon plus ribavirin in HIV-infected Asian patients with acute or chronic HCV infection. HIV-infected Taiwanese patients with acute HCV infection received peginterferon plus weight-based ribavirin for 24 weeks (n = 24), and those with chronic HCV genotype 1 or 6 (HCV-1/6) and HCV genotype 2 or 3 (HCV-2/3) infection received response-guided therapy for 12-72 and 24-48 weeks, respectively (n = 92). The primary endpoint was sustained virologic response (SVR), defined as undetectable HCV RNA 24 weeks off-therapy. The SVR rates were 83% and 72% in patients with acute and chronic HCV infection (p = 0.30), and 68% and 72% in patients with chronic HCV-1/6 and HCV-2/3 infection (p = 0.48), respectively. While no factors predicted SVR in acute HCV and chronic HCV-2/3 infection, age (odds ratio [OR] per 1-year increase: 0.88, 95% confidence interval [CI]: 0.78-0.99, p = 0.04), HCV RNA (OR per 1-log10 increase: 0.18, 95% CI: 0.03-0.98, p = 0.03), IL28B genotype (OR: 5.52, 95% CI: 1.55-12.2, p = 0.02), and RVR (OR: 9.62, 95% CI: 3.89-15.3, p = 0.007) predicted SVR in chronic HCV-1/6 infection. In conclusion, the SVR rates of peginterferon plus ribavirin for 24 weeks and for response-guided 12-72 weeks are satisfactory in HIV-infected Taiwanese patients with acute and chronic HCV infection.

No MeSH data available.


Related in: MedlinePlus